Therefore, we hypothesized that TMEM88 may modulate the prognosis of CRC by altering the sensitivity of cancer cells to chemotherapy through mediation of promoter methylation, although further investigation is needed to confirm this. The gene discussed is TMEM88; the disease is cancer.